Alpha-2-Macroglobulin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Alpha-2-Macroglobulin is a blood protein that blocks a wide range of enzymes, sold as a knee injection. The one proper trial in 75 people found it no better than platelet-rich plasma or a steroid shot, and the authors said the extra cost is not worth it.
Evidence grade for Alpha-2-Macroglobulin: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, 75 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 75
- Human studies
- 1
- Found nothing
- 1
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 75 people given it
6 effects reported, 4 unwanted, 2 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Injury, healing and recovery, Immune system and inflammation, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a large blood protein that traps and switches off a wide range of enzymes. Clinics concentrate it from your own blood and inject it into a sore knee.
What people take it for
- Knee arthritis pain.
- Living longer, because a long lived rodent carries more of it.
What studies in people showed
The knee shot has actually been tested, which is rare for something sold this way. 75 people with painful knee arthritis were split by chance between this, platelet rich plasma, and a steroid shot. Nobody involved knew which. 68 finished 12 weeks. Within its own group, this one improved on the pain scale and three function scores. The platelet group improved on none. The steroid group improved on one. But the comparison between groups showed no difference. The authors concluded it is not better, and that its higher preparation cost may not be worth it. There was no dummy injection group. No study has tested it for ageing in any species.
What people report
Reports, not study results
The good
- Within its own group, people's pain and function scores did improve over 12 weeks.
- It is made from your own blood, which avoids the risks that come with a donor.
The bad
- It did not beat platelet rich plasma or a cheap steroid shot.
- The trial authors said its higher cost may not be worth it for routine use.
- There was no dummy injection group, and a painful knee improves a lot on placebo alone.
- Marketing links it to long life and to naked mole rats. No study has tested it for ageing in any species.
Where these come from: The trial numbers, the cost conclusion and the rodent comparison all come from the studies on this page. No clinic or patient account is quoted.
My bottom line
Tested head to head and it tied with the cheap option. If your knee hurts, start with the cheaper shot.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Alpha-2-Macroglobulin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Joint and knee pain75 people · 1 study · 1 found nothing
- Pain75 people · 1 study · 1 found nothing
- Living longerno headcount stated · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Alpha-2-Macroglobulin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Cancer and tumours1 animal or lab study
32 of the 36 indexed goals have no study of any kind behind Alpha-2-Macroglobulin
No study in people, animals or cells on this page reports a result for these. That does not prove Alpha-2-Macroglobulin does nothing for them. It does mean anything you have heard about Alpha-2-Macroglobulin and one of these did not come from a study cited here.
Show full evidence
What is Alpha-2-Macroglobulin?
Alpha-2-Macroglobulin is a blood protein that blocks a wide range of enzymes, sold as a knee injection. The one proper trial in 75 people found it no better than platelet-rich plasma or a steroid shot, and the authors said the extra cost is not worth it.
The knee injection has actually been tested, which is unusual for anything sold this way. A trial at one hospital took 75 people with painful knee arthritis, at the middle grades of severity. They were split by chance between an A2M-rich concentrate, ordinary platelet-rich plasma, and a steroid shot, all injected into the knee. Nobody involved knew which. They were followed for 12 weeks and 68 of the 75, about 91 percent, finished. By 12 weeks the A2M group had improved on the pain scale and on three function scores. The platelet-rich plasma group improved on none of them. The steroid group improved on one. The result that settles it is the comparison between groups: the changes from start to 12 weeks were no different across the three. The authors concluded that A2M works about as well as platelet-rich plasma and steroids, that the improvement was small and patchy across measures, and that given its higher preparation cost it may not be worth using routinely for knee arthritis.
No trial has tested A2M for ageing, long life or any use that treats the whole body.
Alpha-2-macroglobulin is a large blood protein that traps and switches off a wide range of enzymes. Two separate interests meet here. The longevity interest comes from the naked mole rat, a rodent that lives a long time and rarely gets cancer. A 2015 comparison found its blood carries roughly twice the A2M of human blood, 8.3 against 4.4 milligrams per millilitre, with less total protein, more enzyme-blocking power, and a different sugar coating. A 2019 human study found that sugar coating changes with age.
The knee interest is commercial, and it is why this page carries community reports. A2M is concentrated from the patient's own blood and injected into arthritic joints. It is sold on the idea that it blocks the enzymes that eat away at cartilage.
How does Alpha-2-Macroglobulin work?
This part of the human biology is settled. A2M is a large blood protein built from four linked pieces. It works like a trap: an enzyme bites a bait section, the protein snaps shut around it, and the whole package is cleared through a receptor called LRP1. It can trap enzymes of every main type. The knee injection idea is that it blocks the enzymes that break down cartilage. A 2024 minipig study reported that A2M cut cartilage damage after joint injury by calming inflammation. The longevity idea is a comparison rather than a mechanism. The naked mole rat carries more A2M and more enzyme-blocking power than people do, and the authors suggest that may help explain why it rarely gets cancer and lives so long. No route from A2M to human lifespan has been shown.
What have studies in people found about Alpha-2-Macroglobulin?
One proper trial exists, and its comparison between groups found nothing. It took 75 people, nobody involved knew who got what, and it tested an A2M knee injection against platelet-rich plasma and a steroid shot. A2M improved on several measures within its own group, but the changes were no different across the three treatments. There is no evidence in people for any whole-body or ageing use.
- Controlled trial (Bulletin of the Hospital for Joint Diseases 2024): 75 people with painful knee arthritis at the middle grades of severity, at one hospital, with nobody involved knowing who got what. They joined between June 2018 and May 2019 and were split by chance between an A2M concentrate, platelet-rich plasma and a steroid shot, then followed for 12 weeks. 68 of 75 finished. 73 percent were women, average age 59, range 37 to 75. The groups started out alike in age, sex and x-ray grade.
- The comparison between groups, which is the one that answers the question: the changes in patients' own scores from start to 12 weeks were no different across the three treatments.
- Within each group at 12 weeks: A2M improved on the pain scale and on three function scores. Platelet-rich plasma improved on none of the patient-scored measures. The steroid improved on one.
- The authors' own conclusion: A2M works about as well as platelet-rich plasma and steroids, the improvement was small and patchy across measures, and given its higher preparation cost it may not be worth using routinely for knee arthritis.
- Other human work outside the joint: the sugar coating on A2M changes with age (Cell Biochemistry and Biophysics 2019).
- No study has given A2M to people for ageing, long life or any whole-body use, and none is registered.
What this does not tell you: 75 people at one hospital over 12 weeks cannot pick up small differences between three active treatments. So finding no difference here still leaves room for a real but modest one. Equally, getting better within one group after a knee injection over 12 weeks is exactly what a placebo and natural ups and downs produce. The trial had no salt water or dummy injection group, only three active treatments. Nothing in this trial touches ageing. The naked mole rat work compares the blood of two species and supports no claim about people at all.
What do people who took Alpha-2-Macroglobulin report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- A2M shots are sold in bone, joint and regenerative medicine clinics for knee and other joint arthritis. The protein is concentrated from a sample of the patient's own blood, in the clinic, on the day. It is sold on the idea that it blocks the enzymes that eat away at cartilage.
- The trial that tested this records what the procedure involves and who gets it: people whose knee arthritis shows on x-ray at the middle grades of severity, average age 59, mostly women, given a single shot into the joint.
- The cost of preparing it is a documented problem, not a rumour. The trial authors name the higher cost of preparing A2M as part of why they concluded it may not be worth using routinely, since it did not beat cheaper options.
- The other choices people weigh are the same ones the trial used: platelet-rich plasma and a steroid shot. In that trial, none of the three came out ahead of the others over 12 weeks.
- Marketing for this procedure sometimes links A2M shots to long life or to naked mole rat biology. No study has tested A2M for ageing in any species, and the naked mole rat work is a comparison of two species' blood.
Sources: The published study in the Bulletin of the Hospital for Joint Diseases 2024, which is the source for the procedure description, the population treated, the comparators and the cost conclusion; the 2015 PLoS One naked mole rat comparative study, which is the source of the longevity rationale that appears in marketing. No clinic website, forum post or individual patient account is quoted or relied on here.
The state of the research
This page sits at an odd crossroads. There is a longevity idea borrowed from a long-lived rodent, and there is a commercial knee injection with a real trial behind it. The two have nothing to do with each other, and clinic marketing sometimes borrows the first to sell the second.
The trial is the useful part, and it should be read the way the authors wrote it. A2M improved on four patient-scored measures within its own group, which is the number a clinic would quote. It did not beat platelet-rich plasma or a steroid shot. The study says plainly that its higher preparation cost may not be worth it. That is a head to head result, and it is reported here as evidence, including the part that does not flatter the product. There was no dummy injection group, so the improvement within the A2M group cannot be separated from the large placebo effect that follows any injection into a painful knee.
The naked mole rat comparison is interesting biology, and it is often presented as if it supported taking or injecting A2M. It does not. It reports that a different species carries about twice the blood level and more enzyme-blocking power than people do, with a different sugar coating. No experiment has raised A2M in a mammal to see whether lifespan or cancer rates change.
The evidence, in charts
Fig. 1a · how many people
75people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Bulletin of the Hospital for Joint Diseases 2024 | 75 | 100% |
The whole total is one study of 75. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 4 sources here are studies in people. The rest are not.
- Study in people · done in people250%
- Animal study · done in animals125%
- Lab (cells in a dish) · cells or tissue125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2015 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Alpha-2-Macroglobulin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2024The Effectiveness of Alpha-2-Macroglobulin Injections for Osteoarthritis of the Knee
A2M injections helped knees, but no better than the cheaper options they were tested against. 75 people with moderate knee osteoarthritis were split by chance between an A2M-rich concentrate, ordinary platelet-rich plasma, and a steroid injection. Nobody involved knew which. 68 finished. At 12 weeks the A2M group had improved on every pain and function score, the platelet group on none, and the steroid group on one. But the groups did not differ from each other. The authors concluded A2M is not worth its higher cost.
Double-blinded randomised controlled trial at a single centre, enrolling June 2018 to May 2019. 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis randomised to intra-articular A2M-rich concentrate, conventional platelet-rich plasma, or methylprednisolone, followed 12 weeks; 68 (90.7 percent) completed, 73 percent female, mean age 59. At 12 weeks the A2M group improved significantly on visual analogue scale, WOMAC, KOOS and Tegner; the platelet-rich plasma group improved on nothing; the steroid group improved on Lysholm only. Between-group changes did not differ significantly. The authors concluded A2M is not superior and, given higher preparation cost, may not be justifiable for routine treatment.
- Study in people2019Age-Dependent Variation in Glycosylation Features of Alpha-2-Macroglobulin
Nobody was given anything, and this is not an ageing study in the usual sense. Researchers compared the sugar coating on alpha-2-macroglobulin from newborn umbilical cord blood against pooled adult blood. The total sugar content was the same. The newborn version carried different charges and more branched sugar chains. That may change how quickly the body clears the protein, which could explain why newborns carry more of it. This is a laboratory comparison of two blood pools, not a test of anything.
Human observational. Glycosylation features of alpha-2-macroglobulin vary with age. A measurement of how the protein changes across the lifespan, not a test of any intervention.
- Animal study2024Alpha-2-Macroglobulin Attenuates Posttraumatic Osteoarthritis Cartilage Damage by Inhibiting Inflammatory Pathways With Modified Intra-articular Drilling in a Yucatan Minipig Model
In minipigs, A2M cut cartilage damage after a joint injury by calming inflammation. The model combined an injury to the joint with a drilling technique used to prompt repair.
Minipig. A2M reduced post-traumatic osteoarthritis cartilage damage by inhibiting inflammatory pathways, in a model combining joint injury with modified intra-articular drilling.
- Lab (cells in a dish)2015Analysis of Alpha-2 Macroglobulin from the Long-Lived and Cancer-Resistant Naked Mole-Rat and Human Plasma
A comparison of naked mole rat blood with human blood. The naked mole rat, which lives a long time and rarely gets cancer, carried A2M at 8.3 milligrams per millilitre against 4.4 in human blood. It also had less total protein, more enzyme-blocking power, less enzyme activity and a different sugar coating that makes the protein heavier. The authors suggest this may help explain that animal's resistance to cancer and its long life. This is a comparison of two species' blood, not a treatment.
Comparative analysis of naked mole rat and human plasma. Naked mole rat plasma carried A2M at 8.3 plus or minus 0.44 mg/mL versus 4.4 plus or minus 0.20 mg/mL in human plasma, with lower total plasma protein (38.7 versus 61.7 mg/mL), higher antitryptic activity, lower proteolytic activity, and a different predicted glycosylation giving a higher molecular weight. The authors suggest a possible contribution to that species' cancer resistance and longevity. This is comparative biochemistry, not an intervention.
Common questions
Has Alpha-2-Macroglobulin been tested in people?
Yes. 75 people given it across 1 completed trial cited here, 1 of which found nothing. Alpha-2-Macroglobulin is a blood protein that blocks a wide range of enzymes, sold as a knee injection. The one proper trial in 75 people found it no better than platelet-rich plasma or a steroid shot, and the authors said the extra cost is not worth it.
What is the Alpha-2-Macroglobulin dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 75 people given it
Is Alpha-2-Macroglobulin FDA-approved?
No alpha-2-macroglobulin product is FDA approved for any use. Shots offered by bone and joint doctors are made from the patient's own blood, on the spot. No approval exists for any ageing or longevity use.
Do A2M knee injections work?
In the one proper trial, 75 people with knee arthritis got A2M, platelet-rich plasma or a steroid shot. The A2M group improved on four patient-scored measures over 12 weeks. But the changes were no different across the three groups. The authors concluded A2M is not better, and that its higher preparation cost may not be worth it. There was no dummy injection group.
Is A2M a longevity treatment?
No study has tested it for ageing in any species. The longevity idea comes from a 2015 comparison showing that naked mole rats, which live long and rarely get cancer, carry about twice the blood A2M of people, with more enzyme-blocking power. That is a difference between two species. It is not evidence that raising A2M does anything in a person.
How does A2M compare to platelet-rich plasma?
In the head to head trial they came out the same. A2M improved on the pain scale and three function scores within its own group, while platelet-rich plasma improved on none. But the comparison between groups, which is the one that answers the question, found no difference between A2M, platelet-rich plasma and the steroid at 12 weeks.
Is it safe?
The trial had 68 of 75 people finish 12 weeks and reported no safety problem. But 75 people over 12 weeks is a very small safety record. The injection is made from the patient's own blood, which avoids the risks that come with a donor, and it carries the usual risks of any injection into a joint.